Virus isolated from an outbreak of poliomyelitis in Finland has been examined serologically and at the molecular level. The causative agent was an antigenically unusual strain of type 3 poliovirus, which was unrelated to the strains used to manufacture either live or killed poliovaccines. It is likely that the antigenic properties of the virus played a part in establishing a limited outbreak of poliomyelitis in a vaccinated population.
BaintonD.,
FreemanM.,
MagrathD. I.,
SheffieldF.,
SmithJ. W. G.1979; Immunity of children to diphtheria, tetanus and poliomyelitis. British Medical Journal i:854–857
EvansD. M.,
MinorP. D.,
SchildG. C.,
AlmondJ. W.1983; Critical role of an eight amino acid sequence of VP1 in neutralisation of poliovirus type 3. Nature, London 304:459–462
FergusonM.,
Yi-HuaQi,
MinorP. D.,
MagrathL. D.,
SpitzM.,
SchildG. C.1982; Monoclonal antibodies specific for the Sabin vaccine strain of poliovirus 3. Lancet ii:122–124
FergusonM.,
EvansD. M. A.,
MagrathD. I.,
MinorP. D.,
AlmondJ. W.,
SchildS. C.1985; Induction of broadly reactive, type specific neutralising antibody to poliovirus type 3 by synthetic peptides. Virology 143:505–515
FergusonM.,
MagrathL. D.,
MinorP. D.,
SchildG. C.1986; WHO collaborative study on the use of monoclonal antibodies for the intratypic differentiation of poliovirus strains. Bulletin of the World Health Organization (in press)
MinorP. D.,
SchildG. C.,
FergusonM.,
MackayA.,
MagrathD. I.,
JohnA.,
YatesP. J.,
SpitzM.1982; Genetic and antigenic variation in type 3 polioviruses: characterization of strains by monoclonal antibodies and T1 oligonucleotide mapping. Journal of General Virology 61:167–176
MinorP. D.,
EvansD. M. A.,
FergusonM.,
SchildG. C.,
WestropG.,
AlmondJ. W.1985; Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3. Journal of General Virology 65:1159–1165
NottayB. K.,
KewO. M.,
HatchM. H.,
HeywardJ. T.,
ObijeskiJ. F.1981; Molecular variation of type 1 vaccine related and wild polioviruses during replication in humans. Virology 108:405–423